🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

ELOX ELOX

Company Profile ↓
$17.88
+62.40% 1Y
P/E-3.32
52W High$18.45
52W Low$10.95
EPS (TTM)$-5.39

Company Overview

ELOX (ELOX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 50.3%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 54.1%.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -100.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-
1 Year:-100.00%

Stock Price Performance

1 Year:+62.40%
6 Months:-
3 Months:-
1 Month:+63.29%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 92% of range
$10.95 $18.45
Trend Signals
  • RSI (14)71.82 · Overbought
Price Performance
1M+63.29%
1Y+62.40%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 50.3%.
  • Healthy ROCE of 54.1%.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-3.32
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
-100.00%
Earnings (YoY)
-

Profitability & Returns

ROCE
54.07%
ROE
50.35%
ROA
-
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.08
EPS (TTM)
$-5.39

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
0.53
Debt
-
Total Assets
$8.50M
Current Assets
$8.50M
Working Capital
$-7.58M

Ownership

Promoter Holding
26.28%
Chg in Prom Hold
-
FII / Inst Holding
60.70%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$0
EBITDA
$-4.95M
Free Cash Flow
$-31.91M
Operating Cash Flow
$-6.33M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2011Mar 2012Sep 2012Dec 2012Mar 2013Sep 2013Dec 2013Mar 2014Sep 2014Dec 2014Mar 2015Sep 2015Dec 2015Mar 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2025Mar 2026
Revenue 200.00K--0------------------------------------
Operating Income -1.46M-1.11M-1.25M-1.30M-1.04M-1.75M-1.59M-2.13M-5.19M-10.75M-1.22M-1.15M-3.76M-4.89M-2.21M-1.51M-2.63M-3.18M-4.00M--8.55M-13.54M-11.36M-11.98M-14.31M-12.78M-13.77M-7.59M-6.30M-8.41M-35.73M-10.24M-10.95M-10.30M-7.14M-5.48M-4.14M-3.64M-1.22M-3.79M
Net Income -1.53M-1.06M-2.09M-1.27M-836.58K-1.78M-1.62M-2.15M-5.18M-10.75M-1.23M-180.74K-3.86M-3.08M-933.58K-789.83K-2.68M-3.88M-4.04M-10.60M-8.59M-13.41M-11.16M-11.92M-14.45M-12.88M-13.95M-7.89M-6.62M-8.69M-36.06M-9.88M-11.62M-10.62M-7.51M-6.23M-4.34M-3.59M-1.71M-3.75M
Diluted EPS -------------------------------0.54-0.11-5.36-4.90-3.47-2.88-1.96-1.31-0.45-0.08
R&D Expense 751.52K540.79K513.43K591.08K492.85K810.94K730.82K966.34K2.12M1.37M235.25K601.58K594.50K576.44K280.24K207.38K2.35M2.60M3.28M8.40M4.39M4.15M5.42M6.02M7.34M6.80M4.77M3.70M3.40M4.07M----------

Profit & Loss (Annual)

Figures in USD.

Metric Jun 1999Jun 2000Jun 2001Jun 2002Jun 2003Jun 2004Jun 2005Jun 2006Jun 2007Jun 2008Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Dec 2015Jun 2016Dec 2016Jun 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue --------------7.82K182.23K----------006.36M0
Cost of Revenue ------------------------------
Gross Profit ------------------------------
Operating Expenses --------------------------34.42M17.29M8.83M6.44M
Operating Income -------------7.92M-5.41M-4.65M-9.15M-18.08M-6.28M-11.19M-9.84M-4.59M-20.39M-47.56M-50.55M-33.45M--34.42M-17.29M-2.47M-6.44M
EBITDA ---------------------------33.42M-15.09M-1.83M-4.95M
Interest Expense --------------------------1.95M1.15M1.14M1.05M
Pretax Income ---------------------------36.06M-17.05M-3.14M-6.00M
Tax Provision ------------------------------
Net Income -1.17M-3.35M-2.03M-3.02M-2.78M-3.73M-2.98M-3.31M-3.25M-4.60M-5.73M-13.38M-7.27M-5.07M-6.12M-9.23M-18.06M-6.41M-8.27M-9.85M-5.80M-21.21M-47.19M-50.87M-34.58M--36.06M-17.05M-3.14M-6.00M
Diluted EPS ---------------------------183.15-72.93-9.24-5.39
R&D Expense ------------3.72M2.57M2.09M3.34M4.57M5.84M2.18M8.99M733.66K16.40M20.49M26.35M14.59M-----

Balance Sheet (Annual)

Figures in USD.

Metric Jun 1998Jun 1999Jun 2000Jun 2001Jun 2002Jun 2003Jun 2004Jun 2005Jun 2006Jun 2007Jun 2008Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Dec 2014Jun 2015Dec 2015Jun 2016Dec 2016Jun 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --------------6.95M7.10M33.33M-19.55M-9.23M3.13M5.85M24.78M50.72M58.95M26.48M45.14M21.12M1.71M2.98M5.27M
Total Equity 0912.17K1.52M-206.71K4.79M2.86M4.73M5.59M2.95M2.69M9.84M5.67M7.98M4.52M3.45M3.79M27.49M2.77M12.22M643.00K4.56M610.00K871.21K21.36M42.91M36.21M10.23M22.38M-10.66M-22.60M-24.34M-11.91M
Cash & Equivalents 0-----------8.03M3.61M2.00M1.60M6.11M1.74M3.33M1.37M810.81K2.21M33.20K24.05M48.61M22.49M24.67M42.27M19.21M1.13M111.00K4.79M
Long Term Debt -------------------------10.50M6.38M12.00M8.56M1.61M00
Total Liabilities --------------3.50M3.31M5.84M-7.32M-4.67M-4.97M-7.81M22.73M16.25M22.75M31.78M24.31M27.31M17.18M
Current Liabilities --------------3.16M3.21M1.83M-778.52K-368.99K2.52M2.77M3.42M7.81M11.81M9.84M9.96M23.09M22.70M27.31M17.18M

Cash Flows (Annual)

Figures in USD.

Metric Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Dec 2015Jun 2016Dec 2016Jun 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -5.39M-4.39M-3.90M-4.87M--5.74M--8.84M--15.94M-31.37M-39.39M-28.17M-35.00M-31.84M-14.34M-4.71M-6.33M
Investing Cash Flow -686.42K-450.50K-529.04K646.94K-1.49M--36.00K--114.00K-317.00K-33.52M33.79M2.06M-66.00K309.00K38.00K1.00K
Financing Cash Flow 1.66M3.23M4.03M8.73M-3.88M-9.74M-37.95M56.18M46.80M-3.44M50.79M8.81M-4.08M3.44M11.00M
Capital Expenditure -2.03K-4.46K-1.28K-3.19K-122.64K-10.00K-0-36.00K-2.50K-237.00K-235.00K-40.00K--89.00K-66.00K---
Free Cash Flow -5.39M-4.39M-3.90M-4.87M--5.75M--8.88M--16.17M-31.60M-39.43M--35.09M-31.91M---
Dividends Paid ---------000------

Ratios (Annual)

Figures in %.

Metric Jun 1999Jun 2000Jun 2001Jun 2002Jun 2003Jun 2004Jun 2005Jun 2006Jun 2007Jun 2008Jun 2009Jun 2010Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Dec 2015Jun 2016Dec 2016Jun 2017Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------------------------------
Operating Margin % ---------------59,476.9%-5,019.9%-------------38.8%-
Net Margin % ---------------78,303.4%-5,062.4%-------------49.4%-
ROE % -128.2%-220.4%983.9%-63.1%-97.3%-78.8%-53.3%-112.3%-120.9%-46.8%-101.0%-167.7%-160.9%-146.7%-161.7%-33.6%-147.8%-996.3%-181.3%-1,614.3%-665.3%-99.3%-110.0%-140.5%-338.0%-338.3%75.5%12.9%50.3%
ROCE % --------------142.7%-119.7%-29.0%-96.3%--126.4%-1,613.1%-149.5%-95.5%-110.8%-107.2%-201.1%-1,748.9%82.4%10.1%54.1%

Shareholding Pattern

Insiders
26.28%
Institutions
60.70%
Public Float
82.35%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for ELOX

Yahoo Finance ue, 09 Jun 2026

Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature st…

ELOX — Frequently Asked Questions

What is the current share price of ELOX?

As of 2026-08-05 17:25 PDT, ELOX trades at $17.88 on NASDAQ/NYSE. Its 52-week range is $10.95 to $18.45.

What is the P/E ratio of ELOX?

ELOX trades at a trailing price-to-earnings (P/E) ratio of -3.32.

What is the return on equity (ROE) of ELOX?

ELOX has a return on equity (ROE) of 50.35%. Its return on capital employed (ROCE) is 54.07%.

Is ELOX a good stock to buy?

This page provides a data-driven analysis of ELOX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space